Association of High LAT1 Expression with Poor Prognosis and Recurrence in Colorectal Cancer Patients Treated with Oxaliplatin-Based Adjuvant Chemotherapy

被引:6
|
作者
Shibasaki, Yuta [1 ]
Yokobori, Takehiko [2 ]
Sohda, Makoto [1 ]
Shioi, Ikuma [1 ]
Ozawa, Naoya [1 ]
Komine, Chika [1 ]
Suga, Kunihiko [1 ]
Nakazawa, Nobuhiro [1 ]
Osone, Katsuya [1 ]
Shiraishi, Takuya [1 ]
Okada, Takuhisa [1 ]
Sano, Akihiko [1 ]
Sakai, Makoto [1 ]
Ogawa, Hiroomi [1 ]
Kaira, Kyoichi [3 ]
Shirabe, Ken [1 ]
Saeki, Hiroshi [1 ]
机构
[1] Gunma Univ, Grad Sch Med, Dept Gen Surg Sci, Maebashi 3718510, Japan
[2] Gunma Univ Initiat Adv Res GIAR, Div Integrated Oncol Res, Maebashi 3718511, Japan
[3] Saitama Univ Hosp, Comprehens Canc Ctr, Int Med Ctr, Dept Resp Med, Hidaka 3501298, Japan
基金
日本学术振兴会;
关键词
L-type amino acid transporter-1; cancer aggressiveness; prognostic marker; chemosensitivity marker; TRANSPORTER; FLUOROURACIL; LEUCOVORIN; LEVAMISOLE; RESISTANCE; THERAPY; ASCT2;
D O I
10.3390/ijms24032604
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The mammalian target of rapamycin (mTOR) is often activated in several cancers. We focused on two mTOR regulatory mechanisms: oxaliplatin-induced mTOR signaling and L-type amino acid transporter 1 (LAT1)-induced mTOR activation. High LAT1 expression in several cancers is associated with mTOR activation and resistance to chemotherapy. However, the significance of LAT1 has not yet been elucidated in colorectal cancer (CRC) patients treated with post-operative adjuvant chemotherapy. Immunohistochemistry was conducted to examine the significance of membrane LAT1 expression in 98 CRC patients who received adjuvant chemotherapy, including oxaliplatin. In vitro analysis was performed using CRC cell lines to determine the effects of LAT1 suppression on proliferation, oxaliplatin sensitivity, and mTOR signaling. LAT1 expression was associated with cancer aggressiveness and poor prognosis in 98 CRC patients treated with adjuvant chemotherapy. We found that positive LAT1 expression correlated with shorter survival in 43 patients treated with the capecitabine-plus-oxaliplatin (CAPOX) regimen. LAT1 suppression in CRC cells inhibited the proliferation potency and oxaliplatin-induced activation of mTOR signaling, and improved oxaliplatin sensitivity. LAT1 evaluation before adjuvant treatment may therefore be a sensitive marker for oxaliplatin-based regimens. Moreover, LAT1 may be a promising target for patients with refractory CRC.
引用
收藏
页数:13
相关论文
共 50 条
  • [21] Polymorphisms in p53, GSTP1 and XRCC1 predict relapse and survival of gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy
    Huang, Zhao-Hui
    Hua, Dong
    Du, Xiang
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 64 (05) : 1001 - 1007
  • [22] XRCC1 and GSTP1 polymorphisms and prognosis of oxaliplatin-based chemotherapy in colorectal cancer: a meta-analysis
    Ye, Fanghui
    Liu, Zhenfang
    Tan, Aihua
    Liao, Ming
    Mo, Zengnan
    Yang, Xiaobo
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (03) : 733 - 740
  • [23] Oxaliplatin-Based Adjuvant Chemotherapy in Older Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 12 Trials
    Gallois, Claire
    Shi, Qian
    Pederson, Levi D.
    Andre, Thierry
    Iveson, Timothy J.
    Sobrero, Alberto F.
    Alberts, Steven
    de Gramont, Aimery
    Meyerhardt, Jeffrey A.
    George, Thomas
    Schmoll, Hans-Joachim E.
    Souglakos, Ioannis
    Harkin, Andrea
    Labianca, Roberto
    Sinicrope, Frank A.
    Oki, Eiji
    Shields, Anthony F.
    Boukovinas, Ioannis
    Kerr, Rachel
    Lonardi, Sara
    Yothers, Greg
    Yoshino, Takayuki
    Goldberg, Richard M.
    Taieb, Julien
    Papamichael, Demetris
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (19) : 2295 - 2305
  • [24] Chemotherapy-Associated Hepatopathy in Korean Colorectal Cancer Liver Metastasis Patients: Oxaliplatin-Based Chemotherapy and Sinusoidal Injury
    Nam, Soo Jeong
    Cho, Jai Young
    Lee, Hye Seung
    Choe, Gheeyoung
    Jang, Ja June
    Yoon, Yoo-Seok
    Han, Ho-Seong
    Kim, Haeryoung
    KOREAN JOURNAL OF PATHOLOGY, 2012, 46 (01) : 22 - 29
  • [25] MALAT1 Is Associated with Poor Response to Oxaliplatin-Based Chemotherapy in Colorectal Cancer Patients and Promotes Chemoresistance through EZH2
    Li, Peilong
    Zhang, Xin
    Wang, Haiyan
    Wang, Lili
    Liu, Tong
    Du, Lutao
    Yang, Yongmei
    Wang, Chuanxin
    MOLECULAR CANCER THERAPEUTICS, 2017, 16 (04) : 739 - 751
  • [26] Intermittent Withdrawal of Oxaliplatin for Alleviating Neurotoxicity during Oxaliplatin-Based Chemotherapy for Japanese Patients with Inoperable or Metastatic Colorectal Cancer: A Phase 2 Multicenter Study
    Kato, Shunsuke
    Imai, Hiroo
    Gamoh, Makio
    Takahata, Takenori
    Ohori, Hisatsugu
    Yasuda, Katsuhiro
    Niitani, Tomohito
    Murakawa, Yasuko
    Amagai, Kenji
    Isobe, Hideki
    Shindo, Yoshiaki
    Kuroki, Michio
    Sakamoto, Yasuhiro
    Shimodaira, Hideki
    Yoshioka, Takashi
    Ishioka, Chikashi
    TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE, 2018, 245 (01): : 21 - 28
  • [27] ERCC1 and ERCC2 polymorphisms predict the clinical outcomes of oxaliplatin-based adjuvant chemotherapy in colorectal cancer
    Shi, Lei
    Wang, Ran
    Wu, Wen-ming
    Huang, Yi-fei
    AFRICAN JOURNAL OF PHARMACY AND PHARMACOLOGY, 2012, 6 (32): : 2429 - 2432
  • [28] Pooled analysis of combination antiemetic therapy for chemotherapy-induced nausea and vomiting in patients with colorectal cancer treated with oxaliplatin-based chemotherapy of moderate emetic risk
    Shimokawa, Mototsugu
    Hayashi, Toshinobu
    Nishimura, Junichi
    Satoh, Taroh
    Fukunaga, Mutsumi
    Matsui, Reiko
    Tsuji, Yasushi
    Mizuki, Fumitaka
    Kogawa, Takahiro
    BMC CANCER, 2021, 21 (01)
  • [29] Impact of tumor and node stages on the efficacy of adjuvant oxaliplatin-based chemotherapy in stage III colon cancer patients: an ACCENT pooled analysis
    Cohen, R.
    Raeisi, M.
    Chibaudel, B.
    Yothers, G.
    Goldberg, R. M.
    Bachet, J. -B
    Wolmark, N.
    Yoshino, T.
    Schmoll, H. -J
    Haller, D. G.
    Kerr, R.
    Lonardi, S.
    George, T. J.
    Shacham-Shmueli, E.
    Shi, Q.
    Andre, T.
    de Gramont, A.
    ESMO OPEN, 2025, 10 (03)
  • [30] A retrospective cohort study of metastatic colorectal cancer patients treated with oxaliplatin-based chemotherapy, with an exploratory analysis of changing serum carcinoembryonic antigen levels
    Ng, Say Liang
    Burns, William I.
    Snyder, Raymond D.
    Newnham, Genni M.
    Mclachlan, Sue-Anne
    Liew, Danny
    Dowling, Anthony J.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2012, 8 (02) : 172 - 179